$KRYS
Krystal Biotech, Inc. Stock $krys

$krys Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000171127922000016 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.91M	$8.150M
YoY Change	95.19%	236.78%
% of Gross Profit
Research & Development	$9.314M	$6.201M
YoY Change	50.2%	75.91%
% of Gross Profit
Depreciation & Amortization	$462.0K	$438.0K
YoY Change	5.48%	30.75%
% of Gross Profit
Operating Expenses	$50.22M	$14.35M
YoY Change	249.91%	141.39%
Operating Profit	-$50.22M	-$14.35M
YoY Change	249.91%	141.39%
Interest Expense	$0.00	$1.492M
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$49.97M	-$15.81M
YoY Change	216.03%	196.07%
Income Tax
% Of Pretax Income
Net Earnings	-$49.97M	-$15.81M
YoY Change	215.99%	196.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.99	-$0.74
Diluted Earnings Per Share	-$1.99	-$0.74
COMMON SHARES
Basic Shares Outstanding	25.11M shares	21.25M shares
Diluted Shares Outstanding	25.11M shares	21.25M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$434.6M	$403.4M
YoY Change	7.74%	116.08%
Cash & Equivalents	$269.3M	$402.2M
Short-Term Investments	$165.3M	$1.248M
Other Short-Term Assets	$3.366M	$2.400M
YoY Change	40.25%	50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$438.0M	$405.8M
YoY Change	7.93%	115.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$136.9M	$33.88M
YoY Change	304.12%	162.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$33.34M
YoY Change
Other Assets	$157.0K	$109.0K
YoY Change	44.04%	-97.21%
Total Long-Term Assets	$178.9M	$37.19M
YoY Change	380.95%	121.38%
TOTAL ASSETS
Total Short-Term Assets	$438.0M	$405.8M
Total Long-Term Assets	$178.9M	$37.19M
Total Assets	$616.9M	$443.0M
YoY Change	39.24%	116.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.209M	$1.844M
YoY Change	345.17%	207.33%
Accrued Expenses	$51.94M	$7.100M
YoY Change	631.51%	121.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$60.44M	$9.144M
YoY Change	560.95%	123.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.883M	$3.200M
YoY Change	146.34%	18.52%
Total Long-Term Liabilities	$7.883M	$3.200M
YoY Change	146.34%	18.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$60.44M	$9.144M
Total Long-Term Liabilities	$7.883M	$3.200M
Total Liabilities	$68.32M	$12.37M
YoY Change	452.48%	81.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$190.7M	-$87.00M
YoY Change	119.2%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$548.6M	$430.7M
YoY Change
Total Liabilities & Shareholders Equity	$616.9M	$443.0M
YoY Change	39.24%	116.0%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$49.97M	-$15.81M
YoY Change	215.99%	196.05%
Depreciation, Depletion And Amortization	$462.0K	$438.0K
YoY Change	5.48%	30.75%
Cash From Operating Activities	-$15.49M	-$9.654M
YoY Change	60.48%	55.03%
INVESTING ACTIVITIES
Capital Expenditures	$17.19M	$2.473M
YoY Change	595.15%	63.99%
Acquisitions
YoY Change
Other Investing Activities	-$38.72M	$1.730M
YoY Change	-2337.98%	765.0%
Cash From Investing Activities	-$55.91M	-$747.0K
YoY Change	7384.34%	-42.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$107.0K	$152.3M
YoY Change	-99.93%	62560.08%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$542.0K	$144.3M
YoY Change	-100.38%	59284.36%
NET CHANGE
Cash From Operating Activities	-$15.49M	-$9.654M
Cash From Investing Activities	-$55.91M	-$747.0K
Cash From Financing Activities	-$542.0K	$144.3M
Net Change In Cash	-$71.94M	$133.9M
YoY Change	-153.73%	-1937.06%
FREE CASH FLOW
Cash From Operating Activities	-$15.49M	-$9.654M
Capital Expenditures	$17.19M	$2.473M
Free Cash Flow	-$32.68M	-$12.13M
YoY Change	169.51%	56.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001711279
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38210
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Krystal Biotech, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1080209
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 Wharton Street
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 701
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Pittsburgh
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	15203
CY2022Q1	dei	City Area Code CityAreaCode	412
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	586-5830
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2022Q1	dei	Trading Symbol TradingSymbol	KRYS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25635138	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	269303000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	341246000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8453000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7228000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	165329000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	96850000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3366000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4171000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	437998000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	442267000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136927000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112355000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	33339000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	64371000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	74000	USD
CY2022Q1	us-gaap	Assets Assets	616874000	USD
CY2021Q4	us-gaap	Assets Assets	626295000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8209000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8398000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1411000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1041000	USD
CY2022Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	50817000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16297000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	60437000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25736000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7883000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6983000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	68320000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	32719000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2061773	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2061773	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25199081	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25207985	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25207985	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	740500000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	734523000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1197000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-163000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190749000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140784000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	548554000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	593576000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	616874000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	626295000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9314000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6201000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15908000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8152000	USD
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	25000000	USD
CY2021Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	50222000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	14353000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50222000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14353000	USD
CY2022Q1	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	257000	USD
CY2021Q1	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	33000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1492000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49965000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15812000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1034000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50999000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15815000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.99
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.99
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25114453	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25114453	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21253508	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21253508	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	593576000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	649000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6571000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1034000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49965000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	548554000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	292084000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	152033000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2350000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15812000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	430652000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49965000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15812000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1015000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	536000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6430000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2313000	USD
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2021Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	1492000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-135000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	12000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-820000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1312000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-9000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2022Q1	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-126000	USD
CY2021Q1	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-77000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-554000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	294000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2013000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	276000	USD
CY2022Q1	krys	Increase Decrease Accrued Legal Settlement And In Process Research And Development IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment	25000000	USD
CY2021Q1	krys	Increase Decrease Accrued Legal Settlement And In Process Research And Development IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15493000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9654000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9654000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17191000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2473000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	62754000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	24037000	USD
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	1726000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55908000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-747000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	152264000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	649000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2022Q1	krys	Payments For Suit Liability PaymentsForSuitLiability	0	USD
CY2021Q1	krys	Payments For Suit Liability PaymentsForSuitLiability	7960000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-542000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	144304000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-71943000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	133903000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341246000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268269000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	269303000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	402172000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14507000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2615000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1394000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	krys	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	24000	USD
CY2021Q1	krys	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	214000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190700000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	434600000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3226962	shares
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div>
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1423540	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49965000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15812000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25114453	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25114453	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21253508	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21253508	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.99
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.99
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022Q1	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	469170000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1201000	USD
CY2022Q1	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	467971000	USD
CY2021Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	502636000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	180000	USD
CY2021Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	502467000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	141603000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	116569000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4676000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4214000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136927000	USD
CY2022Q1	krys	Cumulative Escalation Clause Term CumulativeEscalationClauseTerm	P5Y
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112355000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	462000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	438000	USD
CY2022Q1	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	2647000	USD
CY2021Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1602000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4168000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2011000	USD
CY2022Q1	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	1560000	USD
CY2021Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	2882000	USD
CY2022Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	149000	USD
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	83000	USD
CY2022Q1	krys	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	17097000	USD
CY2021Q4	krys	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	9606000	USD
CY2022Q1	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	54000	USD
CY2021Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	26000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	25000000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	142000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	87000	USD
CY2022Q1	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	50817000	USD
CY2021Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	16297000	USD
CY2020Q1	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	USD
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	10000000	USD
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	10000000	USD
CY2020Q4	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	USD
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	USD
CY2020Q4	us-gaap	Escrow Deposit EscrowDeposit	1500000	USD
CY2022Q1	krys	Lessor Operating Lease Liability Annual Lease Payments LessorOperatingLeaseLiabilityAnnualLeasePayments	82000	USD
CY2022Q1	krys	Cumulative Escalation Clause Percent CumulativeEscalationClausePercent	0.10
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1115000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1510000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1539000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1277000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1277000	USD
CY2022Q1	krys	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	12063000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18781000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9487000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9294000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8453000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7228000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1411000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1041000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7883000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6983000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9294000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8024000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P14Y4M24D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	409000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	218000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	49000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	37000	USD
CY2021Q3	krys	Loss Contingency Guaranteed Maximum Price To Be Paid LossContingencyGuaranteedMaximumPriceToBePaid	82300000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	25000000	USD
CY2022Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	301000	USD
CY2022Q1	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	768000	USD
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	227000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	198000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2043179	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	57.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31331000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1179500	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	62.53
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1475	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	37.34
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	68342	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	36000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	61.24
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3152862	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.99
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30364000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	439954	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	44.52
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10929000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	808000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	141000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	37000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M26D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M19D

Files In Submission

Name	View Source	Status
0001711279-22-000016-index-headers.html	Edgar Link	pending
0001711279-22-000016-index.html	Edgar Link	pending
0001711279-22-000016.txt	Edgar Link	pending
0001711279-22-000016-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
krys-20220331.htm	Edgar Link	pending
krys-20220331.xsd	Edgar Link	pending
krys-20220331ex311.htm	Edgar Link	pending
krys-20220331ex312.htm	Edgar Link	pending
krys-20220331ex321.htm	Edgar Link	pending
krys-20220331_cal.xml	Edgar Link	unprocessable
krys-20220331_def.xml	Edgar Link	unprocessable
krys-20220331_g1.jpg	Edgar Link	pending
krys-20220331_htm.xml	Edgar Link	completed
krys-20220331_lab.xml	Edgar Link	unprocessable
krys-20220331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRYS
Krystal Biotech, Inc. Stock $krys

2022 Q1 Form 10-Q Financial Statement

#000171127922000016 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS Krystal Biotech, Inc. Stock $krys

2022 Q1 Form 10-Q Financial Statement

#000171127922000016 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS
Krystal Biotech, Inc. Stock $krys